Norris Medicines
- Market cap
- ₹ 15 Cr.
- 52-week range
- 12 – 20.06
- ROCE
- 3.4%
- Dividend yield
- 0%
- Sector
- Commercial Services & Supplies
- Industry
- Trading & Distributors
- Listed on
- BSE
About
Norris Medicines Limited is an India-based company, which is focused on the health care industry. The Company is engaged in the manufacturing and exporting medicines and injections. The Company’s product categories include antibiotic, anti-inflammatory and analgesic range, G. I. range, dermatological range, nutrition range, anti-malaria, anti-emetic, cough/cold range, dental range, diabetics and cardiac, and miscellaneous range. Its antibiotic products include Arizon-100, Arizon-250, Arizon-500, Cefan-dry syurp, and Cefan DT-50. Its G.I. products include Denzym Syrup, Denzym Oral Drop, Ezynor-20, Regus-DSR, Sucrinor and Rinotac. Its dermatological products include Clobec-G, Gabax, Morfit Plus, Novadin-M, Silwon-C and Tioderm. Its nutrition products include Cand XP, Cand Fort, Can D suspension and Hemfit Plus Syrup. It has two plants situated at GIDC, Ankleshwar, Gujarat. Both the plants of the Company are World Health Organization Good Manufacturing Practices (WHO GMP) approved.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Trading & Distributors: 197 companies →Norris Medicines against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Sales growth−37% against a typical −1.7% from a year earlier.100th of 142
- Share price, 3 months−1.3% against a typical −4.8%.68th of 167
- Size₹ 15 Cr. market value against a typical ₹ 26.5 Cr. (1st = largest).118th of 182
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 3 | 1 | 1 |
| Expenses | 3 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 1 |
| Operating Profit | −0 | −0 | 0 | −0 | −0 | −0 | 0 | −0 | −0 | 1 | 0 | −0 |
| OPM % | −9.4% | −6.2% | 32.2% | −22.2% | −11.8% | −2.7% | 2.6% | −6.9% | −24.5% | 29.1% | 21.3% | −30.4% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −0 | −0 | 0 | −0 | −0 | −0 | −0 | −0 | −1 | 1 | 0 | −0 |
| Tax % | 0% | 0% | 34.6% | 0% | 0% | 0% | 35.3% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −0 | −0 | 0 | −0 | −0 | −0 | −0 | −0 | −1 | 1 | 0 | −0 |
| EPS in Rs | −0.48 | −0.27 | 0.17 | −0.37 | −0.36 | −0.28 | −0.23 | −0.31 | −0.72 | 0.7 | 0.05 | −0.4 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −8%
- 5 Years
- −8%
- 3 Years
- −1%
- TTM
- 16%
- 10 Years
- —
- 5 Years
- 14%
- 3 Years
- 23%
- TTM
- 69%
- 10 Years
- —
- 5 Years
- 11%
- 3 Years
- 11%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
Peers
Listed companies in the same business.
| Norris Medicines | ₹ 14.62 | ₹ 15 Cr. | — | — | — | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Vimal Dhirendra Shah
- Executive Director, Managing Director
- Priyanka Lohiya
- Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.